Research on discovering and developing new drugs. Covers structure-revealing tools, eye-disease mechanisms, protein screening, and once-daily oral medicines.
Researchers at IISc create a novel technique to coat droplets in composite shells containing oil-loving and hydrophobic particles. This method offers flexible shell thickness control over a wide range, enabling the encapsulation of droplets with different sizes.
Researchers have identified promising treatment candidates for morphine tolerance and cancer, as well as a biomarker for kidney injury. A monoclonal antibody targeting the mu-opioid receptor has been shown to alleviate morphine tolerance and physical dependence, while inducing excessive mitochondrial fission in tumor cells. Additionall...
Scientists at IPC PAS create peptide-based sensors to detect inflammation and chronic diseases, offering a promising alternative to traditional methods. The study uses phage-display method to identify CRP-binding peptides, achieving higher affinity and detection efficiency than antibodies.
Researchers have provided new details on structures resulting from 3D domain swapping in antibody light chains, shedding light on mechanisms of protein aggregation. The study suggests that the formation of tetramers may prevent protein aggregation by decreasing flexibility.
Researchers at University of Cincinnati Cancer Center present Phase 2 clinical trial results for a new BTK inhibitor treatment that offers potential for improved efficacy and safety in chronic lymphocytic leukemia. The study also explores the use of IRAK4 inhibitors to target acute myeloid leukemia cells, with promising results.
Researchers at the University of Turku found that bexmarilimab therapy alters macrophage behavior to promote anti-tumor immune defense. The therapy was well-tolerated and stabilized disease progression in patients with advanced-stage cancer, inducing tumor-associated macrophage and lymphocyte activation.
A new experimental model, human precision-cut lung slices (hPCLS), was used to study lung disease mechanisms and understand treatment response. The team leveraged single-cell genomics to analyze cell activity in hPCLS after specific treatments.
Researchers have discovered that a nanoemulsion made from copaiba oil has antiviral effects against zika virus, showing 80% viral RNA inhibition. The study's results pave the way for developing medications or specific vaccines against zika.
Researchers discovered how biological information travels between mothers and babies during pregnancy. Microscopic extracellular vesicles, produced by placental cells, act as a protective mechanism transporting important biological information to emerging neurons.
CureSHANK is offering $250,000 grants to researchers studying SHANK3-related epilepsy in Phelan-McDermid syndrome. The goal is to improve mechanistic and clinical knowledge of this treatment-resistant form of epilepsy.
Researchers have developed new tools to assess disease progression of Alzheimer's disease in animal models, providing a translational approach for studying the disease. The tools use neuroimaging and network modeling techniques to analyze metabolic changes in the brain, confirming previous clinical findings.
A team of researchers successfully synthesized a 1.5-million-year-old antibiotic called paleomycin, which displays potent properties against human pathogens. By tracing the evolutionary path of glycopeptide antibiotics, the team gained insights into the development of new drugs and uncovered a common precursor molecule.
Researchers analyzed leishmaniasis lesions on mouse skin to detect metabolic signaling pathways that differed from uninfected mice. They found pathways with pain-relief properties tied to the brain's endocannabinoid system, which is involved in a host of physiological processes, including the pain response.
Disrupted health care markets have changed the creation, provision, and consumption of health care. Marketing strategies need to account for new producers, providers, and consumers. The editorial calls for a research agenda outlining opportunities for marketing scholars to examine the impact of disrupted exchanges on consumer welfare.
Researchers at Kyoto University developed a new reactant demonstrating efficacy on proteins with drug-resistant mutations. The new inhibitor, ArNASA, reacts with lysine residues and is highly stable in physiological environments.
Researchers at the University of Bath have created a novel bacterial system to mass-produce cyclic proteins and peptides, addressing a significant bottleneck in the development of new therapeutic treatments. By harnessing the natural cyclization process from the Oldenlandia flower, they improved heat and chemical stability, as well as ...
Researchers at iGCORE in Japan developed two synthetic versions of an ADP-ribose fragment to study cellular functions. The approach enables the production of structurally well-defined oligo- and poly(ADP-ribose) samples, accelerating ADP-ribose biology research.
The study reveals that mutations of the p53 protein are critical for driving cancer growth, and its loss-of-function is the primary contributor. Researchers used CRISPR to remove mutated versions of the protein and found no evidence of gain-of-function contributing to cancer growth.
Researchers have developed a new method, SECRE, to identify genetic regulators of cytokine secretion in autoimmune diseases. The technique has been validated on cells known to play a crucial role in inflammatory bowel disease (IBD) and shows promising results for treating conditions with few therapeutic options.
Researchers at Cornell University have found that silica-based C’Dots can be taken up by the bloodstream after oral administration, making them a potential therapeutic delivery method. The particles' ability to induce ferroptosis, a cell death program, may also provide health benefits due to their natural presence in food.
Researchers have successfully mapped the entire HLA class II landscape, predicting how pathogens are displayed on cell surfaces. The mapping reveals that multiple HLA variants play essential roles in autoimmune disorders and organ rejection, highlighting their potential for developing immunotherapy treatments.
Scientists at ETH Zurich used AI to analyze data from 1,380 borylation reactions and predict optimal synthesis methods for new drugs. The model was tested on six known drug molecules and showed a success rate of five out of six cases.
A team of researchers has found a way to get antibacterial drugs through the outer membrane of Pseudomonas aeruginosa, making it more vulnerable to treatment. By using machine learning and testing various compounds, they discovered how to create new compounds that can penetrate the bacterium's defenses.
Researchers at University of Eastern Finland developed a new method for accurate determination of water content in water-soluble compounds, utilizing solution-state nuclear magnetic resonance spectroscopy. The method is simple, accurate and quick, with results comparable to traditional methods like TGA and X-ray crystallography.
Researchers at Chalmers University of Technology have discovered a new method for capturing proteins in nano-sized traps to study difficult-to-treat diseases. The technique allows for the trapping of hundreds of proteins in a small volume, enabling the study of early development and potential drug countermeasures.
Researchers developed an ingestible capsule to measure vital signs from within the GI tract, detecting sleep apnea episodes and breathing rate depression. The device shows promise for early detection of respiratory changes, including those caused by opioids or asthma/COPD.
A small molecule called YM022 has been discovered to block aversive memory formation in mice, offering a new direction for developing anti-depressants. The study found that YM022 suppressed neuroplasticity-caused aversive memory formation and reduced depressive behaviors in mice.
Jenny Wilkerson receives $1.94 million grant to develop novel models and investigate antinociceptive profiles of basal sex hormone alterations in patients with chronic post-op pain. The study aims to answer questions about the impact of altered sex hormone levels on recovery times, drug effectiveness, and long-term health.
Researchers have created a reliable and efficient method to add fluorine to molecules, increasing pharmaceutical drug efficiency. The iron and sulfur-based reaction enables the release of fluorine from carboxylic acids and its incorporation into alkenes, common building blocks for drugs.
Experts have developed a reliable method to predict the free energy of crystals, addressing the challenge of understanding physical properties and environmental factors. The new approach uses high-performance computing and has been successfully applied to seven pharmaceutical companies.
A novel device, ecO2, produces oxygen at the site to keep cells alive for up to a month in vitro or weeks in vivo. This innovation improves the outcomes of cell-based therapies for diseases and injuries by increasing metabolic demand.
Researchers developed a technique to capture extracellular vesicles using sustainable wood cellulose-based nanofiber sheets, revealing new insights into cancer treatment. The technology has the potential to revolutionize early cancer diagnosis and open up personalized medicine.
Researchers at the University of Illinois have developed a new antifungal molecule that targets fungal cells without harming human kidney cells or other tissues. The molecule, dubbed AM-2-19, has shown significant efficacy against various fungal infections in vitro and in vivo studies.
Researchers at Texas A&M University have found a correlation between flavonoid compounds and reduced endometriosis symptoms. Flavonoids like Quercetin and Kaempferol show promise in easing inflammation, with studies suggesting they may help suppress the symptoms of inflammatory diseases like endometriosis.
Researchers from Incheon National University create gelatin patches that generate molecular oxygen to accelerate wound healing. The new hydrogels demonstrate improved coagulation, blood closure, and neovascularization in both in vitro and in vivo experiments.
Researchers developed a new class of drugs targeting PRMT5 enzyme, exploiting genetic vulnerability in tumor suppressor genes. Early clinical trials show promising results for patients with specific types of cancer, including melanoma and mesothelioma.
Researchers at St. Jude Children's Research Hospital have determined the structure of vesicular monoamine transporter 2 (VMAT2), a protein crucial for packaging and releasing neurotransmitters in neurons. The study provides critical information for drug development to treat hyperkinetic disorders like Tourette syndrome.
A study by University of Texas Health Science Center at San Antonio researchers found that corticotropin-releasing factor (CRF) activates immune cells in the dura membrane under the skull, leading to pain signals. This discovery may lead to the development of a small-molecule drug therapy to inhibit CRF and MrgprB2 interaction.
A three-year USDA grant will train healthcare and social workers in five high-risk rural Missouri counties to address childhood trauma and reduce opioid overdoses. The training covers topics such as ACEs, positive childhood experiences, and trauma-informed care.
A team of researchers aims to develop drug therapies by targeting genes that affect metabolism in people with Down syndrome, potentially improving their quality of life. The project will focus on the protein SIM2, which has been linked to breast cancer and metabolic changes in individuals with the condition.
Scientists have discovered the open and closed states of the coronavirus E ion channel, which could help develop antiviral drugs to reduce inflammation. The study's findings provide insights into the channel's structure and function, allowing researchers to design molecules that can bind to it and prevent inflammation.
Researchers identified new biological markers and pathways to develop improved therapies for endometrial cancer. The study found that in-frame indels in the PIK3R1-AKT pathway promote tumor growth and provide potential targets for controlling or stopping cancer progression.
Researchers at the University of Birmingham have created binding molecules to make platelets clump together, enabling validated clinical assays and research tools for studying platelet activation. The 'nanobody' technology shows promise for developing therapeutics for blood and thrombotic disorders.
Researchers discovered that inhibiting the BRAF/EGFR/MEK pathway significantly reduced cancer stemness and drug resistance in primary colorectal cancer cells. The study also identified a triple combination treatment against BRAF, EGFR, and MEK as a promising approach to block these activities and develop effective treatments.
A clinical trial led by Western Sydney University's NICM Health Research Institute has revealed that Sailuotong, a novel herbal extract, shows promise as a potential treatment for mild cognitive impairment. The study found improvements in memory and executive function in participants taking SLT compared to those on a placebo.
Researchers at the University of Virginia Health System are developing computer models to better understand the cellular processes and gene activity of multi-drug resistant bacteria Staphylococcus aureus and Pseudomonas aeruginosa. The goal is to identify vulnerabilities in these bacteria and advance the development of new treatments.
A University at Buffalo-led research team has developed molecules that can transport chloride ions across cell membranes, increasing airway surface liquid and restoring normal mucus clearance in cystic fibrosis cells. The synthetic anion binders offer a new potential treatment for the chronic disease.
Researchers discovered the STAT3 signaling pathway as a potential target for treating H3K27M-mutant diffuse midline gliomas (DMGs), a uniformly lethal central nervous system malignancy. The current standard of care, including palliative radiation and chemotherapy, remains ineffective in this disease.
A new cancer drug candidate has been found to restore the effectiveness of the immune system in fighting tumors, including melanoma, bladder cancer, leukemia, and colon cancer. The drug works by lowering a toxic compound called MTA, which impairs normal functioning of immune cells and blocks immunotherapies.
A study found that people with a specific genetic mutation in the CARD9 gene have higher IL-17 protein levels, making them more responsive to IL-17 inhibitor biologics. This discovery may lead to targeted treatment recommendations for ankylosing spondylitis patients.
The University of Oklahoma is part of a $104 million federal initiative to study antibiotic resistance, led by Harvard Medical School professor Johan Paulsson. The project aims to understand how antibiotic resistance arises and characterize rare cells that survive during antibiotic treatments.
A new national ALS research consortium, Access for All in ALS, has been launched with a $16.7 million NIH award. The consortium will include 34 clinical sites nationwide and generate a longitudinal biorepository linked to detailed clinical information.
Researchers at UVA Health System have developed a powerful new tool to understand how medications affect men and women differently. The model has provided unprecedented insights into biological processes in the liver, helping ensure that new medications will not cause harmful side effects.
USC is partnering with seven leading regenerative medicine institutes to form the Los Angeles and surrounding area regenerative medicine consortium. The partnership aims to advance regenerative medicine using stem cells and gene therapies for treating unmet medical needs.
A University of Virginia team has developed a new analytical tool using hydrogels to cultivate vascular sprouting from mouse lung tissue, providing new insight into idiopathic pulmonary fibrosis. The research aims to understand the biomechanical and biochemical cues to blood vessels in the lungs during disease progression.
A team of scientists has developed a method to detect active Cullin-RING ligases (CRLs), which are responsible for destroying unwanted proteins in cells. The new technology, called a molecular radar, reveals which CRLs are deployed to address cellular stresses and perform the actions of some anti-cancer drugs.
A recent study published in the Journal of Chemical Information and Modeling presents a significant breakthrough in accelerating giga-scale virtual screens using machine learning. The researchers successfully reduced processing time by 10-fold for 1.56 billion drug-like molecules, identifying top-scoring compounds in under ten days.
Researchers from MedUni Vienna developed a new approach to fighting resistant cell lines in small cell lung cancer by combining two already available therapeutic agents. The study reveals the molecular mechanism underlying therapy resistance and provides a promising basis for research into successful new therapies.
Researchers used AI to predict 3D shapes of over 215 million proteins, providing insights into their functions and evolution. The Protein Universe Atlas offers a valuable resource for scientists to explore protein diversity.
Researchers at University of Chicago identified a new pain relief pathway in the brain that produces powerful analgesic effects without tolerance or addictive risks. Targeting acetylcholine receptors, particularly alpha-7, offers a promising path to developing non-opioid painkillers.